ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 251 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $0 | -100.0% | 25,700 | -7.2% | 0.00% | -100.0% |
| Q3 2022 | $29,000 | +163.6% | 27,700 | +177.0% | 0.00% | +100.0% |
| Q2 2022 | $11,000 | -92.6% | 10,000 | -31.7% | 0.00% | -87.5% |
| Q1 2022 | $148,000 | -82.4% | 14,646 | -88.9% | 0.01% | -77.1% |
| Q4 2021 | $843,000 | +563.8% | 132,505 | +378.4% | 0.04% | +483.3% |
| Q3 2021 | $127,000 | +6250.0% | 27,700 | +9133.3% | 0.01% | – |
| Q2 2021 | $2,000 | -86.7% | 300 | -98.7% | 0.00% | – |
| Q1 2021 | $15,000 | +275.0% | 23,300 | +7666.7% | 0.00% | – |
| Q4 2020 | $4,000 | -55.6% | 300 | -91.4% | 0.00% | -100.0% |
| Q2 2020 | $9,000 | -59.1% | 3,500 | -34.0% | 0.00% | 0.0% |
| Q1 2020 | $22,000 | -87.6% | 5,300 | -34.6% | 0.00% | -90.9% |
| Q4 2019 | $178,000 | +19.5% | 8,100 | -76.6% | 0.01% | -21.4% |
| Q3 2019 | $149,000 | +43.3% | 34,573 | -53.3% | 0.01% | +55.6% |
| Q2 2019 | $104,000 | -55.4% | 74,100 | +152.2% | 0.01% | -62.5% |
| Q1 2019 | $233,000 | +126.2% | 29,378 | +100.3% | 0.02% | +166.7% |
| Q4 2018 | $103,000 | -3.7% | 14,667 | -41.6% | 0.01% | +12.5% |
| Q3 2018 | $107,000 | -10.8% | 25,100 | -28.4% | 0.01% | -20.0% |
| Q2 2018 | $120,000 | -88.9% | 35,041 | -72.0% | 0.01% | -89.4% |
| Q1 2018 | $1,085,000 | +89.0% | 125,136 | +118.1% | 0.09% | +308.7% |
| Q4 2017 | $574,000 | -30.1% | 57,371 | -18.7% | 0.02% | -25.8% |
| Q3 2017 | $821,000 | -24.7% | 70,544 | -38.9% | 0.03% | -22.5% |
| Q2 2017 | $1,091,000 | -40.0% | 115,534 | -28.3% | 0.04% | -46.7% |
| Q1 2017 | $1,819,000 | +215.3% | 161,173 | -53.8% | 0.08% | +257.1% |
| Q4 2016 | $577,000 | -50.6% | 348,797 | +65.3% | 0.02% | -59.6% |
| Q3 2016 | $1,168,000 | +59.3% | 211,050 | +100.5% | 0.05% | +40.5% |
| Q2 2016 | $733,000 | +28.6% | 105,242 | -47.7% | 0.04% | 0.0% |
| Q1 2016 | $570,000 | -69.9% | 201,209 | +11.0% | 0.04% | -64.8% |
| Q4 2015 | $1,893,000 | – | 181,188 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |